Pharmaceutical

Merus gets grant for treatment of clec12a positive cancer with bispecific antibody

Discover a groundbreaking patent for treating CLEC12A positive cancer with bispecific antibodies. Learn about a unique dosing strategy to target cancer cells effectively while sparing hemopoietic stem cells.

May 1, 2024 - 00:00
Discover a groundbreaking patent for treating CLEC12A positive cancer with bispecific antibodies. Learn about a unique dosing strategy to target cancer cells effectively while sparing hemopoietic stem cells.
Read the original article

Tags:

Previous Article

Corcept Therapeutics gets grant for method of preparing compound of formula i

Next Article

Pacira BioSciences gets grant for method for treating spasticity in a patient’s ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Vampiric cancer cells, a brain atlas, & alleged misconduct at Cassava

STAT+: Vampiric cancer cells, a brain atlas, & alleged ...

Oct 16, 2023

Labeling Excellence: The Art and Science Behind Capmatic's Advanced Labeling Solutions

Labeling Excellence: The Art and Science Behind Capmati...

Aug 28, 2023

UniQure sells part of Hemgenix royalty rights in deal worth up to $400 million

UniQure sells part of Hemgenix royalty rights in deal w...

May 16, 2023